- Recursion Pharmaceuticals RXRX+16.63% (RXRX) surges 16.38% on heavy volume, trading near $4.83 intraday high. - Extended 2029 Tempus AI TEM +8.11% partnership replaces $84M potential fees with $42M ...

Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...

Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug ...

Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.

Recursion Pharmaceuticals Inc. surged as breakthrough AI-driven drug discovery progress fueled bullish sentiment, and stocks ...

As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The ...

Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from ...

I was able to correctly eliminate the wrong options in the recursion function fill-in-the-blank question. However, I was ...

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive ...

Communications leaders are leaning on plain language, trusted voices and face-to-face interactions to reach splintered and skeptical audiences, experts said.